{"assertionCriteria": {"method": "ClinGen PAH ACMG Specifications v1", "citation": {"url": "https://submit.ncbi.nlm.nih.gov/ft/byid/i2ra5ppm/clingen_pah_acmg_specifications_v1.pdf"}}, "clinicalSignificance": {"citation": [{"url": "https://erepo.clinicalgenome.org/evrepo/ui/interpretation/43c0e463-29fc-4579-ad14-55bf5d1fab63"}], "clinicalSignificanceDescription": "Pathogenic", "comment": "This c.320A>G (p.His107Arg) variant in PAH was reported in 22 patients with PAH deficiency (>120 uMol/L Phe), detected in trans in 16 patients with pathogenic variants p.Arg111*, p.Arg400Thr, p.Val399=, p.Val399=, p.Arg241Cys, p.Arg241Cys, p.Arg413Pro, p.Gly257Val, p.His107Arg, p.Arg243Gln, p.His220Pro, p.Arg176*, p.Arg243Gln, p.Arg243Gln, p.Val230Ile, p.Ile65Thr (PMID: 28982351). Computational evidence for this variant is conflicting; predicted to be tolerated (SIFT), disease-causing (MutationTaster) and benign (PolyPhen2). This variant is present in European (Non-Finnish) populations at extremely low frequencies in gnomAD (MAF=0.00002), ExAC (MAF=0.00001), and 1000 Genomes (MAF=0.00099). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3_very-strong, PP4.", "dateLastEvaluated": "2020-12-09", "modeOfInheritance": "Autosomal recessive inheritance"}, "conditionSet": {"condition": [{"db": "MONDO", "id": "MONDO:0009861"}]}, "localID": "43c0e463-29fc-4579-ad14-55bf5d1fab63", "localKey": "43c0e463-29fc-4579-ad14-55bf5d1fab63", "observedIn": [{"collectionMethod": "curation", "alleleOrigin": "germline", "affectedStatus": "unknown", "numberOfIndividuals": 0}], "recordStatus": "novel", "releaseStatus": "public", "variantSet": {"variant": [{"gene": [{"symbol": "PAH"}], "hgvs": "NC_000012.12:g.102894767T>C"}]}}